Amphastar Pharmaceuticals
AMPH
25.54
-0.37
-1.43%
Amphastar Pharmaceuticals
US · AMPH
#3194 by market cap
25.54
-0.37
-1.43%
Live - 5344 symbols - heartbeat 207s ago
· 2026-10-08 08:29
Pre-market
25.54
0.00%
After-hours
25.54
0.00%
- Market cap
- 1.09B
- P/E (TTM)i
- 15.11
- P/Bi
- 1.41
- EPSi
- 2.03
- Div yieldi
- 0.00%
- 52W posi
- 69%
Reader sentiment
Are you bullish or bearish on AMPH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.43, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -1.65% YoY
Margins
- Gross margin
- 49.46%
- Operating margin
- 19.50%
- Net margin
- 13.63%
Key ratios & quality
- Enterprise valuei
- 1.42B
- PEG ratioi
- 6.33
- Altman Z-Scorei
- 2.43
PEG uses trailing P/E against the 3-year net income growth rate (2.39%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 294.67M | 322.36M | 349.85M | 437.77M | 498.99M | 644.40M | 731.97M | 719.89M |
| Gross profit | 106.99M | 131.92M | 143.34M | 199.74M | 248.86M | 351.12M | 373.86M | 356.06M |
| Selling & admin expenses | 58.04M | 63.11M | 65.16M | 68.92M | 66.59M | 80.39M | 94.52M | 129.81M |
| Research & development | 57.56M | 68.85M | 67.23M | 60.93M | 74.77M | 73.74M | 73.91M | 85.84M |
| Operating profit | -8.62M | -39.00K | 10.95M | 69.89M | 107.50M | 196.99M | 205.42M | 140.40M |
| Pretax profit | -9.93M | 60.23M | 4.64M | 84.14M | 116.04M | 171.36M | 189.76M | 123.62M |
| Tax | -3.27M | 13.72M | 3.54M | 20.63M | 23.48M | 31.83M | 29.67M | 25.53M |
| Net profit | -6.66M | 46.51M | 1.10M | 63.30M | 91.39M | 137.55M | 159.52M | 98.09M |
| Basic EPS | 0 | 1 | 0 | 1 | 2 | 3 | 3 | 2 |
| Diluted EPS | -0.12 | 0.98 | 0.03 | 1.25 | 1.74 | 2.60 | 3.06 | 2.03 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 170.53M | 174.41M | 191.84M | 183.11M | 171.17M | 183.90M |
| Gross profit | 85.25M | 86.49M | 98.65M | 85.67M | 70.32M | 93.47M |
| Selling & admin expenses | 27.86M | 24.23M | 50.97M | 26.75M | 29.96M | 31.58M |
| Research & development | 20.10M | 20.08M | 22.35M | 23.31M | 26.74M | 22.16M |
| Operating profit | 37.29M | 42.18M | 25.32M | 35.61M | 13.63M | 39.73M |
| Pretax profit | 30.86M | 39.34M | 21.51M | 31.91M | 10.05M | 38.54M |
| Tax | 5.58M | 8.31M | 4.16M | 7.49M | 3.63M | 8.20M |
| Net profit | 25.29M | 31.03M | 17.35M | 24.43M | 6.42M | 30.35M |
| Basic EPS | 1 | 1 | 0 | 1 | 0 | 1 |
| Diluted EPS | 0.51 | 0.64 | 0.37 | 0.51 | 0.14 | 0.67 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 220.34M | 255.24M | 279.68M | 318.12M | 378.32M | 489.60M | 534.07M | 636.02M |
| Cash & ST investments | 89.17M | 85.36M | 105.62M | 136.67M | 175.76M | 256.81M | 221.65M | 282.81M |
| Inventory | 69.32M | 110.50M | 96.83M | 92.81M | 103.58M | 105.83M | 153.74M | 176.89M |
| Total assets | 513.56M | 586.97M | 631.24M | 671.53M | 741.99M | 1.51B | 1.58B | 1.63B |
| Total current liabilities | 106.83M | 90.01M | 112.20M | 103.81M | 94.86M | 225.41M | 173.76M | 158.16M |
| Short-term debt | 18.23M | 10.92M | 15.62M | 5.18M | 6.05M | 4.34M | 7.04M | 9.57M |
| Long-term debt | 31.98M | 39.39M | 34.19M | 74.78M | 72.84M | 589.58M | 601.63M | 608.75M |
| Total liabilities | 149,204,000.00 | 159,443,000.00 | 182,513,000.00 | 226,007,000.00 | 213,329,000.00 | 873,491,000.00 | 845,172,000.00 | 840,494,000.00 |
| Total equity | 364.36M | 427.53M | 448.72M | 445.52M | 528.66M | 639.42M | 732.30M | 788.81M |
| Retained earnings | 67.49M | 116.37M | 117.77M | 180.34M | 271.72M | 409.27M | 568.79M | 666.88M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 587.96M | 580.83M | 639.47M | 636.02M | 633.68M | 630.95M |
| Cash & ST investments | 236.88M | 231.75M | 276.21M | 282.81M | 291.95M | 290.12M |
| Inventory | 185.48M | 191.73M | 185.93M | 176.89M | 170.19M | 179.91M |
| Total assets | 1.63B | 1.62B | 1.67B | 1.63B | 1.65B | 1.74B |
| Total current liabilities | 199.05M | 176.41M | 205.23M | 158.16M | 164.48M | 263.21M |
| Short-term debt | 7.97M | 8.81M | 8.75M | 9.57M | 11.38M | 11.29M |
| Long-term debt | 603.86M | 607.73M | 608.58M | 608.75M | 609.80M | 609.56M |
| Total liabilities | 874,993,000.00 | 857,851,000.00 | 889,476,000.00 | 840,494,000.00 | 874,771,000.00 | 975,609,000.00 |
| Total equity | 751.28M | 757.48M | 776.75M | 788.81M | 773.39M | 768.16M |
| Retained earnings | 594.07M | 625.10M | 642.45M | 666.88M | 673.30M | 703.65M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 38.19M | 41.76M | 57.27M | 97.99M | 89.18M | 183.50M | 213.39M | 156.12M |
| Depreciation & amortization | 16.52M | 21.12M | 25.18M | 26.53M | 28.28M | 41.78M | 57.21M | 63.20M |
| Free cash flow | -8.62M | 207.00K | 23.41M | 70.54M | 65.15M | 145.34M | 172.35M | 118.98M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 12.99M | -3.99M | -24.43M | -28.87M | -39.91M | -58.14M | -85.46M | -75.59M |
| Ending cash balance | 88.20M | 75.55M | 94.51M | 126.59M | 156.33M | 144.53M | 151.84M | 170.41M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 35.08M | 35.59M | 52.58M | 32.86M | 47.84M | 51.32M |
| Depreciation & amortization | 15.21M | 16.24M | 15.77M | 15.99M | 16.49M | 16.46M |
| Free cash flow | 24.38M | 22.78M | 47.24M | 24.59M | 38.33M | 42.73M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -11.00M | -39.22M | -4.85M | -20.52M | -29.49M | -45.21M |
| Ending cash balance | 183.02M | 187.92M | 216.50M | 170.41M | 171.17M | 223.85M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -1.71 | 13.71 | 0.36 | 14.65 | 18.76 | 23.55 | 23.26 | 12.90 |
| ROA %i | -1.19 | 8.89 | 0.23 | 9.54 | 12.93 | 12.20 | 10.32 | 6.12 |
| ROIC %i | -1.53 | 11.62 | 0.26 | 12.22 | 15.54 | 16.39 | 13.32 | 7.88 |
| 5-year avg ROE %i | -0.49 | 3.05 | 3.32 | 5.62 | 9.15 | 14.21 | 16.12 | 18.62 |
| EBIT margin %i | -3.29 | 18.72 | 1.43 | 19.42 | 23.63 | 30.81 | 30.07 | 20.71 |
| FCF / sales %i | -- | 0.06 | 6.69 | 16.11 | 13.06 | 22.55 | 23.55 | 16.53 |
| Current ratioi | 2.06 | 2.84 | 2.49 | 3.06 | 3.99 | 2.17 | 3.07 | 4.02 |
| Quick ratioi | 1.32 | 1.46 | 1.53 | 2.08 | 2.79 | 1.65 | 2.07 | 2.80 |
| Debt / assetsi | 9.78 | 11.35 | 10.66 | 15.59 | 13.83 | 41.22 | 41.24 | 40.26 |
| LT debt / equityi | 9.62 | 14.61 | 12.84 | 22.33 | 18.26 | 96.85 | 87.88 | 81.95 |
| Interest coveragei | -39.85 | 507.12 | 13.40 | 96.07 | 63.86 | 7.31 | 7.25 | 5.85 |
| Revenue CAGR (3Y) %i | 5.42 | 8.10 | 13.36 | 14.11 | 15.68 | 22.58 | 18.69 | 12.99 |
| Net income CAGR (3Y) %i | -- | 70.81 | -27.27 | -- | 23.14 | 361.10 | 36.94 | 2.39 |
| FCF CAGR (3Y) %i | -- | -77.07 | 78.59 | -- | 580.21 | 83.79 | 34.69 | 22.24 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 19.90 | 18.32 | 14.84 | 12.90 | 10.39 | 10.30 |
| ROA %i | 8.85 | 8.67 | 6.95 | 6.12 | 4.84 | 4.68 |
| ROIC %i | 11.56 | 10.84 | 8.99 | 7.88 | 6.44 | 6.37 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 27.48 | 25.95 | 22.25 | 20.71 | 17.84 | 17.55 |
| FCF / sales %i | 20.56 | 15.21 | 15.35 | 16.53 | 18.45 | 20.94 |
| Current ratioi | 2.95 | 3.29 | 3.12 | 4.02 | 3.85 | 2.40 |
| Quick ratioi | 1.92 | 2.08 | 2.07 | 2.80 | 2.73 | 1.66 |
| Debt / assetsi | 40.12 | 40.58 | 39.42 | 40.26 | 41.65 | 39.47 |
| LT debt / equityi | 85.80 | 85.37 | 83.43 | 81.95 | 87.28 | 88.14 |
| Interest coveragei | 7.17 | 7.30 | 6.37 | 5.85 | 4.99 | 4.91 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Other products is the largest reported line at 35.99% of revenue, across 7 reported segments.
- No single line clears half of revenue; BAQSIMI® is next at 24.74%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Other products35.99%
BAQSIMI®24.74%
Primatene MIST®11.42%
Epinephrine8.62%
Lidocaine8.18%
Glucagon6.47%
Ipratropium bromide4.57%
Quote time 2026-10-08 08:29:55 · For reference only, not investment advice and not tailored to your situation.